Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94917 trials found · Page 145 of 4746
-
New hope for lymphoma patients after CAR t fails: glofitamab trial launches
Disease control Not yet recruitingThis is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New CAR-T shot aims to fight blood cancer without removing cells
Disease control Not yet recruitingThis study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects. DIT101 is an investigational in vivo CAR-T cell therap…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for Drug-Resistant ovarian cancer? phase 3 trial launches
Disease control Not yet recruitingThis is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for myeloma patients: ELDORADO trial tests Next-Gen combo against standard care
Disease control Not yet recruitingThis research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for tough lung cancer: tarlatamab trial targets patients with poor health
Disease control Recruiting nowSTART-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 16, 2026 01:18 UTC
-
Balloon in the aorta may boost survival after cardiac arrest
Disease control Recruiting nowThis study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated May 05, 2026 11:57 UTC
-
New drug duo aims to shrink head and neck tumors in first-line treatment
Disease control Recruiting nowThis study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "s…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for tough lung cancer: phase 3 trial launches
Disease control Not yet recruitingSmall cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and chang…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 16, 2026 01:05 UTC
-
New IV drug could regrow hair in severe alopecia
Disease control Recruiting nowThe purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes t…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Pre-Transplant radiation may boost survival in blood cancer patients with Hard-to-Treat lesions
Disease control Not yet recruitingApplication of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions. This study aims to improve transplantation outcomes with extramedullary lesions. The investi…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
MRNA therapy offers hope for rare hormone disorder
Disease control Recruiting nowXH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 i…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a common diabetes pill protect the brain after a stroke?
Disease control Not yet recruitingBackground: Reperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have de…
Phase: PHASE4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated May 16, 2026 01:05 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human testing
Disease control Recruiting nowThis study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New radioactive drug targets tough prostate cancer
Disease control Recruiting nowAdvanced metastatic castration-resistant prostate cancer is a medical condition for which additional effective and tolerable treatments are urgently needed in order to improve patient outcomes and quality of life. The goal of this clinical trial is to learn more about Actinium (…
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New lupus drug aims for remission without lifelong pills
Disease control Recruiting nowThe purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Can a cancer drug flush out hidden HIV?
Disease control Recruiting nowCombination therapy with antiretroviral medication (ART) has proven effective in keeping HIV suppressed and restoring the immune system, but it cannot cure the infection. Therefore, lifelong treatment is necessary. The reason for this is a reservoir of inactive virus that remains…
Phase: PHASE1 • Sponsor: Thomas Aagaard Rasmussen • Aim: Disease control
Last updated May 16, 2026 01:05 UTC
-
New hope for advanced esophageal cancer: JS212 combo trial launches
Disease control Recruiting nowThis study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Could a vitamin boost TB treatment? new trial underway
Disease control Recruiting nowThe purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
Phase: PHASE2 • Sponsor: Gates Medical Research Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New weekly shot aims to tackle obesity and diabetes together
Disease control Recruiting nowThe purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug combo offers hope for tough head and neck cancers
Disease control Recruiting nowThis is a single-arm, open-label, phase II study to evaluate the efficacy and safety of the combination of the antibodies iparomlimab and tuvonralimab, administered with or without chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M H…
Phase: NA • Sponsor: The Second Affiliated Hospital of Hainan Medical University • Aim: Disease control
Last updated May 11, 2026 20:41 UTC